drugset / Trial / NCT05872867
Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of the present study is to determine the safety, tolerability, and efficacy of WM-A1-3389 in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancer (NSCLC).
Timeline
- Start
- 2024-03-14
- Primary completion
- 2026-02-22
- Completion
- 2026-02-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | WM-A1-3389 | Unknown | — | Intravenous |